Neoleukin Therapeutics (NLTX) Competitors

uniQure (NASDAQ:QURE) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Which has stronger valuation & earnings, QURE or NLTX?

Neoleukin Therapeutics has lower revenue, but higher earnings than uniQure. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$15.84M	39.51	-$308.48M	-$4.96	-2.59
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	-5.57

Do analysts prefer QURE or NLTX?

uniQure presently has a consensus target price of $40.00, suggesting a potential upside of 211.53%. Given uniQure's stronger consensus rating and higher possible upside, research analysts plainly believe uniQure is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, QURE or NLTX?

uniQure has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Does the MarketBeat Community believe in QURE or NLTX?

uniQure received 605 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 70.66% of users gave uniQure an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

Company	Underperform	Outperform
uniQure	Outperform Votes 655 70.66%	Underperform Votes 272 29.34%
Neoleukin Therapeutics	Outperform Votes 50 45.87%	Underperform Votes 59 54.13%

Do insiders and institutionals hold more shares of QURE or NLTX?

78.8% of uniQure shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is QURE or NLTX more profitable?

Neoleukin Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Neoleukin Therapeutics' return on equity of -37.22% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-837.80%	-188.82%	-32.17%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Does the media prefer QURE or NLTX?

In the previous week, Neoleukin Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Neoleukin Therapeutics and 0 mentions for uniQure. Neoleukin Therapeutics' average media sentiment score of 0.92 beat uniQure's score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
uniQure	Neutral
Neoleukin Therapeutics	Positive

Summary

uniQure beats Neoleukin Therapeutics on 10 of the 18 factors compared between the two stocks.